Quick Takeaways
- Robert Hershberg has 7 issuer positions tracked on this page.
- Estimated disclosed ownership value: $1,449,587.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Robert Hershberg
- Location
- Boston, MA
- Summary
- The estimated net worth of Robert Hershberg is at least $1,449,587 dollars as of 06 Mar 2026. Robert Hershberg is the Director of Adaptive Biotechnologies Corp and owns shares of Adaptive Biotechnologies Corp (ADPT) stock worth about $988.8K. Robert Hershberg is the Director of RECURSION PHARMACEUTICALS, INC. and owns shares of RECURSION PHARMACEUTICALS, INC. (RXRX) stock worth about $328.1K. Robert Hershberg is the Director of FATE THERAPEUTICS INC and owns shares of FATE THERAPEUTICS INC (FATE) stock worth about $109.2K. Robert Hershberg is the Director of NanoString Technologies Inc and owns shares of NS Wind Down Co., Inc. stock worth about $23.5K.
- Signature
- /s/ Robert Hershberg by Kyle Piskel, Attorney-in-Fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Robert Hershberg and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: Adaptive Biotechnologies Corp ($988,823).
- Past-year value change for that position: -$367,488.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Official SEC Source
Filed on Form 4
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original FilingOwnership of Robert Hershberg
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| ADPT | Adaptive Biotechnologies Corp | Director | $988,823 | -$367,488 | -27% | 04 Mar 2026 |
| RXRX | RECURSION PHARMACEUTICALS, INC. | Director | $328,107 | 18 Jun 2025 | ||
| FATE | FATE THERAPEUTICS INC | Director | $109,200 | 06 Jun 2023 | ||
| NSTG | NanoString Technologies Inc | Director | $23,457 | 18 Apr 2022 | ||
| HLVX | HilleVax, Inc. | President and CEO, Director | $0 | 17 Sep 2025 | ||
| ATAI | ATAI Life Sciences N.V. | Director | 05 Nov 2025 | |||
| SPRY | Silverback Therapeutics, Inc. | Director | 10 Jun 2022 |
Insider Transactions Reported by Robert Hershberg:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.